Targeted Tissue Proteomic Assays

Expression Pathology is developing targeted, quantitative
mass spectrometry-based assays that can be used to measure
protein expression in standard formalin-fixed paraffin-embedded
(FFPE) tumor samples. The assays include a wide range of drug
target pathway proteins including EFGR, IGF-1R, cMET, cSRC, mTOR,
MEK, and ERK, and their phosphorylation states.

Our assays can be multiplexed and have great potential in drug development, clinical trials and personalized medicine. Measuring protein expression in standard formalin-fixed tissue samples can provide diagnostic and prognostic information to guide treatment decisions.

Absolute quantitation * Multiplexed Assays * Phosphoproteins * Drug Targets

Enabling Technology Platform

Our development program is based on two proprietary technologies; tissue dissection using our DIRECTOR laser microdissection slides, and the ability to solubilize FFPE tissue using the patented Liquid Tissue MS Protein Prep protocol so the sample can be analyzed using a range of different mass spectroscopy applications.

Discover and Validate

Explore archival tissue collections for differentially expressed protein biomarkers. EPI's patented technologies work together to enable protein biomarker discovery and validation in the standard form of patient tissue.

* Companion diagnostics * Prognostic biomarkers * Drug targets

Liquid Tissue® and DIRECTOR® are registered trademarks of Expression Pathology Inc.

Liquid Tissue technology is protected by U.S. Patent 7,473,532 and patents pending and foreign equivalents thereof. DIRECTOR technology is protected by U.S. Patents 7,294,367 and 7,381,440 and foreign equivalents thereof.

. Our Terms and Conditions apply. The Liquid Tissue® MS is sold under a limited license with commercial use restrictions. For further details please contact us.